Your browser is no longer supported. Please, upgrade your browser.
FLDM Fluidigm Corporation monthly Stock Chart
FLDM [NASD]
Fluidigm Corporation
Index- P/E- EPS (ttm)-1.37 Insider Own0.80% Shs Outstand70.40M Perf Week-5.68%
Market Cap420.99M Forward P/E- EPS next Y-0.65 Insider Trans-72.37% Shs Float68.64M Perf Month-48.18%
Income-68.70M PEG- EPS next Q-0.20 Inst Own97.40% Short Float5.25% Perf Quarter-50.17%
Sales119.60M P/S3.52 EPS this Y18.90% Inst Trans4.20% Short Ratio3.70 Perf Half Y-44.27%
Book/sh2.50 P/B2.39 EPS next Y33.70% ROA-24.30% Target Price13.00 Perf Year-11.28%
Cash/sh0.98 P/C6.12 EPS next 5Y-8.06% ROE-61.20% 52W Range5.97 - 14.90 Perf YTD-30.63%
Dividend- P/FCF- EPS past 5Y-18.10% ROI-18.70% 52W High-59.87% Beta2.44
Dividend %- Quick Ratio2.50 Sales past 5Y9.70% Gross Margin56.00% 52W Low0.17% ATR0.55
Employees535 Current Ratio2.90 Sales Q/Q6.80% Oper. Margin-50.70% RSI (14)18.84 Volatility5.28% 7.73%
OptionableYes Debt/Eq0.29 EPS Q/Q52.20% Profit Margin-57.50% Rel Volume0.72 Prev Close6.04
ShortableYes LT Debt/Eq0.29 EarningsAug 01 AMC Payout- Avg Volume973.10K Price5.98
Recom2.00 SMA20-29.95% SMA50-43.01% SMA200-43.46% Volume703,418 Change-0.99%
Mar-15-19Initiated UBS Neutral $14
Jan-03-19Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated Mizuho Buy $11 → $12
Aug-05-16Reiterated Cantor Fitzgerald Buy $13 → $11
May-05-16Reiterated Mizuho Buy $8 → $11
Apr-12-16Reiterated Leerink Partners Outperform $20 → $15
Jan-07-16Initiated Deutsche Bank Buy $18
Oct-30-15Upgrade Cantor Fitzgerald Hold → Buy $15 → $12
Oct-30-15Reiterated Mizuho Neutral $15 → $8
Aug-27-15Initiated Cantor Fitzgerald Hold
Aug-07-15Reiterated Mizuho Neutral $30 → $15
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
May-08-15Reiterated Maxim Group Buy $52 → $44
May-08-15Downgrade Mizuho Buy → Neutral $50 → $30
May-06-14Reiterated Maxim Group Buy $65 → $52
Apr-23-14Upgrade Mizuho Neutral → Buy $43 → $50
Mar-21-14Reiterated Maxim Group Buy $52 → $65
Feb-03-14Reiterated Oppenheimer Outperform $46 → $52
Jan-14-14Reiterated Mizuho Neutral $30 → $43
Aug-21-19 07:48AM  Have Insiders Been Buying Fluidigm Corporation (NASDAQ:FLDM) Shares This Year? Simply Wall St.
Aug-20-19 04:05PM  Fluidigm to Participate in Upcoming Health Care Investor Conferences GlobeNewswire
Aug-05-19 05:44PM  Edited Transcript of FLDM earnings conference call or presentation 1-Aug-19 9:00pm GMT Thomson Reuters StreetEvents -14.41%
04:10PM  Fluidigm is Running in Place, but Expects to Break Out in 2020 Motley Fool
Aug-02-19 01:15PM  Here's Why Fluidigm Is Getting Crushed Today Motley Fool -33.74%
09:24AM  Fluidigm (FLDM) Q2 2019 Earnings Call Transcript Motley Fool
12:41AM  CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results GlobeNewswire
Aug-01-19 04:05PM  Fluidigm Announces Second Quarter 2019 Financial Results GlobeNewswire
04:01PM  Jonathan Day Named VP, Commercial Operations, Americas GlobeNewswire
08:30AM  Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology GlobeNewswire
Jul-30-19 08:30AM  Fluidigm Announces 3rd Annual Imaging Mass Cytometry User Group Meeting GlobeNewswire
Jul-25-19 10:33AM  Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
08:30AM  Bill W. Colston Named to Fluidigm Board of Directors GlobeNewswire
Jul-08-19 07:45AM  Update: Fluidigm (NASDAQ:FLDM) Stock Gained 90% In The Last Year Simply Wall St.
Jul-03-19 01:05PM  Fluidigm Announces Conference Call and Webcast of Second Quarter 2019 Financial Results GlobeNewswire
Jun-20-19 08:30AM  Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019 GlobeNewswire
Jun-19-19 08:30AM  Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research GlobeNewswire
Jun-17-19 08:30AM  Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers GlobeNewswire
Jun-04-19 08:30AM  Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer GlobeNewswire
May-31-19 05:37PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-29-19 08:45AM  Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research GlobeNewswire
08:30AM  Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology GlobeNewswire
May-12-19 09:47PM  Hedge Funds Have Never Been This Bullish On Fluidigm Corporation (FLDM) Insider Monkey
May-10-19 04:05PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-09-19 08:30AM  Fluidigm to Participate in Upcoming Health Care Investor Conferences GlobeNewswire
May-06-19 08:00PM  Fluidigm Delivers Growth Where It Matters Most in Q1 2019 Motley Fool
07:09AM  Edited Transcript of FLDM earnings conference call or presentation 2-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-04-19 09:15AM  Stocks Soar on Strong Jobs Report; NASDAQ at New High Zacks
May-03-19 02:38PM  Here's Why Fluidigm Shares Fell as Much as 14.4% Today Motley Fool -13.15%
01:24AM  Fluidigm (FLDM) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 08:35PM  Fluidigm (FLDM) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:25PM  Fluidigm: 1Q Earnings Snapshot Associated Press
04:05PM  Fluidigm Announces First Quarter 2019 Financial Results GlobeNewswire
04:02PM  Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer GlobeNewswire
May-01-19 10:26AM  Masimo Gets CE Mark for ANI Module, Enhances Root Platform Zacks
Apr-30-19 09:00AM  Fluidigm Announces 8th Annual Mass Cytometry Summit GlobeNewswire
Apr-29-19 09:41AM  Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings? Zacks
Apr-25-19 10:34AM  Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-23-19 06:00AM  What to Watch When Fluidigm Reports Q1 Earnings Motley Fool
Apr-08-19 03:55PM  How Should Investors Feel About Fluidigm Corporation's (NASDAQ:FLDM) CEO Pay? Simply Wall St.
02:49PM  3 Stocks to Hold for the Next 20 Years Motley Fool
Apr-05-19 09:40AM  Here's Why You Should Invest in DENTSPLY (XRAY) Stock Now Zacks
Apr-04-19 04:05PM  Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results GlobeNewswire
Apr-03-19 10:32AM  AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates Zacks
Apr-02-19 10:20AM  Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition Zacks
10:20AM  AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study Zacks
Mar-28-19 08:45AM  Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting GlobeNewswire
08:30AM  Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry GlobeNewswire
Mar-27-19 09:42AM  Look who leased the top floors of South San Francisco's new biotech highrise American City Business Journals
Mar-18-19 05:48PM  Fluidigm Corp (FLDM) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-15-19 08:51AM  Fluidigm (FLDM) in Focus: Stock Moves 8% Higher Zacks
Mar-14-19 11:53AM  Here's Why Fluidigm Rose as Much as 13.4% Today Motley Fool +7.97%
Mar-12-19 09:54AM  Fluidigm Is Emerging From a Large Base Pattern, So Go Long TheStreet.com
Mar-08-19 07:47AM  3 Top Stocks Under $20 Motley Fool
Mar-05-19 08:30AM  Colin McCracken Joins Fluidigm as Chief Commercial Officer GlobeNewswire
Feb-22-19 05:30PM  Fluidigm to Participate in Upcoming Investor Conferences GlobeNewswire
02:33PM  Edited Transcript of FLDM earnings conference call or presentation 7-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-19-19 02:00PM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
08:00AM  Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-12-19 07:00PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
02:23PM  Fluidigm Corporation (NASDAQ:FLDM): Is It A Good Long Term Opportunity? Simply Wall St.
Feb-11-19 05:03PM  The 1 Stock I'd Buy Right Now Motley Fool
Feb-08-19 03:55PM  Here's Why Fluidigm Rose as Much as 14.2% Today Motley Fool +9.36%
Feb-07-19 08:09PM  Fluidigm Corp (FLDM) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:50PM  Fluidigm (FLDM) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:57PM  Fluidigm: 4Q Earnings Snapshot Associated Press
04:05PM  Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
09:00AM  Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations GlobeNewswire
08:30AM  Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases GlobeNewswire
Jan-31-19 08:30AM  Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1 GlobeNewswire
Jan-24-19 07:55AM  Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-14-19 04:05PM  Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Jan-08-19 08:30AM  Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring GlobeNewswire +5.03%
Dec-23-18 09:49PM  Do Hedge Funds Love Fluidigm Corporation (FLDM)? Insider Monkey
Dec-14-18 04:05PM  Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Dec-12-18 01:01AM  Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock GlobeNewswire
Dec-11-18 04:01PM  Fluidigm Announces Commencement of Public Offering of Common Stock GlobeNewswire
Dec-10-18 04:23PM  Edited Transcript of FLDM earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents
Dec-05-18 09:15AM  Recent Gains Cut in Half on Trade, Yield Curve Fears Zacks
Nov-12-18 04:05PM  Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire -5.24%
Nov-09-18 04:05PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-08-18 08:30AM  Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018 GlobeNewswire
Nov-07-18 04:11PM  Fluidigm Recognized as a Company to Watch in 2019 GlobeNewswire +6.15%
Nov-06-18 08:35AM  Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-01-18 07:50PM  Fluidigm (FLDM) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:43PM  Fluidigm: 3Q Earnings Snapshot Associated Press
04:05PM  Fluidigm Announces Third Quarter 2018 Financial Results GlobeNewswire
08:30AM  Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development GlobeNewswire
Oct-31-18 08:30AM  Laura Clague Named to Fluidigm Board of Directors GlobeNewswire
Oct-25-18 08:30AM  Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System GlobeNewswire
Oct-16-18 07:45AM  Market Trends Toward New Normal in Globant S.A, EZCORP, Earthstone Energy, SPX, Fluidigm, and MAG Silver Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-04-18 08:30AM  Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD GlobeNewswire
Oct-01-18 04:15PM  Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results GlobeNewswire
Sep-27-18 04:05PM  Fluidigm Introduces Single-Cell Total RNA Sequencing Applications for C1 GlobeNewswire
Sep-10-18 08:30AM  Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis GlobeNewswire
Sep-07-18 07:30AM  Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD GlobeNewswire
Sep-05-18 06:00PM  Fluidigm to Participate at Upcoming Investor Events in September GlobeNewswire
Aug-15-18 07:45AM  Detailed Research: Economic Perspectives on Middlesex Water, Farmer Brothers, Fluidigm, QCR, Revlon, and Gladstone Land What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-09-18 08:30AM  Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting GlobeNewswire
Aug-06-18 04:05PM  Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levin Easterly Partners LLCPassive InvestorAug 13Sale7.01151,0111,059,2828,271,611Aug 15 05:41 PM
COLELLA SAMUEL DDirectorAug 08Buy6.651,0006,653117,481Aug 12 04:57 PM
COLELLA SAMUEL DDirectorAug 07Buy6.861,0006,857116,481Aug 08 09:04 PM
Levin Easterly Partners LLCPassive InvestorAug 07Sale6.90129,237892,0609,840,084Aug 12 05:05 PM
COLELLA SAMUEL DDirectorAug 06Buy7.028,00056,183115,481Aug 08 09:04 PM
Levin Easterly Partners LLCPassive InvestorAug 01Sale12.251,62919,9569,969,321Aug 05 03:59 PM
Levin Easterly Partners LLCPassive InvestorJul 29Sale11.9782,585988,4609,970,950Jul 29 04:50 PM
Levin Easterly Partners LLCPassive InvestorJul 26Sale11.92195,9822,335,30210,053,535Jul 29 04:50 PM
Levin Easterly Partners LLCPassive InvestorJul 25Sale11.859,405111,48010,249,517Jul 29 04:50 PM
Levin Easterly Partners LLCPassive InvestorJul 24Sale11.7828,090330,99910,258,922Jul 24 05:01 PM
Levin Easterly Partners LLCPassive InvestorJul 23Sale11.5818,601215,41810,287,012Jul 24 05:01 PM
Levin Easterly Partners LLCPassive InvestorJul 22Sale11.5761,432710,90310,305,613Jul 24 05:01 PM
Levin Easterly Partners LLCPassive InvestorJul 19Sale11.5083,728963,12310,367,045Jul 19 04:21 PM
Levin Easterly Partners LLCPassive InvestorJul 18Sale11.50179,8532,068,30310,450,773Jul 19 04:21 PM
Levin Easterly Partners LLCPassive InvestorJul 17Sale11.32134,4871,522,17810,630,626Jul 19 04:21 PM
Levin Easterly Partners LLCPassive InvestorJul 01Sale12.3329,410362,77110,765,113Jul 02 04:35 PM
Levin Easterly Partners LLCPassive InvestorJun 28Sale12.30157,3491,935,48710,794,523Jul 02 04:35 PM
Levin Easterly Partners LLCPassive InvestorJun 25Sale12.2325,452311,38710,951,872Jun 27 06:04 PM
Levin Easterly Partners LLCPassive InvestorJun 24Sale12.29191,6962,355,27310,976,694Jun 27 06:04 PM
COLELLA SAMUEL DDirectorJun 20Option Exercise6.1323,600144,762107,481Jun 24 09:14 PM
BARTHELEMY NICOLASDirectorJun 17Sale12.435,10063,39841,849Jun 19 04:36 PM
Khadder NicholasSee RemarksMay 20Option Exercise0.004,901039,725May 22 09:01 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERMay 20Option Exercise0.004,751040,162May 22 09:02 PM
Kreger Bradley AllenSVP, Global OperationsMay 20Option Exercise0.0012,500012,500May 22 09:00 PM
Linthwaite Stephen ChristopherPresident & CEOMay 20Option Exercise0.0012,5620164,020May 22 09:01 PM
BARTHELEMY NICOLASDirectorMar 23Option Exercise0.002,500042,962Mar 26 05:49 PM
Paya Carlos VDirectorMar 23Option Exercise0.002,500036,856Mar 26 05:49 PM
Linthwaite Stephen ChristopherPresident & CEOFeb 20Option Exercise0.0012,5620156,102Feb 21 09:10 PM
Khadder NicholasSee RemarksFeb 20Option Exercise0.004,901036,829Feb 21 09:09 PM
McPhail StevenChief Commercial OfficerFeb 20Option Exercise0.003,722058,417Feb 21 09:08 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERFeb 20Option Exercise0.004,952037,421Feb 21 09:08 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 24Buy7.798566210,473,809Dec 26 03:40 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 20Buy7.425764,27310,413,365Dec 26 03:40 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 19Buy7.861281,00610,412,789Dec 20 05:07 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 18Buy7.713627810,412,661Dec 20 05:07 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 14Buy7.814132010,412,625Dec 18 03:09 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 12Buy6.751,000,0006,750,00010,404,641Dec 14 06:14 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 10Buy7.7235,000270,2009,970,342Dec 11 03:26 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorDec 07Buy7.95332629,935,342Dec 11 03:26 PM
Linthwaite Stephen ChristopherPresident & CEONov 20Option Exercise0.0012,5620146,650Nov 21 09:07 PM
Khadder NicholasSee RemarksNov 20Option Exercise0.004,901032,530Nov 21 09:06 PM
McPhail StevenChief Commercial OfficerNov 20Option Exercise0.003,720052,055Nov 21 09:06 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERNov 20Option Exercise0.005,051034,217Nov 21 09:07 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorNov 14Buy7.5547,768360,6969,809,695Nov 16 03:01 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorNov 08Buy7.841279969,761,927Nov 13 03:42 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorNov 06Buy7.408556,3269,761,800Nov 08 03:00 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 26Buy7.192,59918,68011,337,342Oct 26 12:30 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 25Buy7.217,36353,09511,334,743Oct 26 12:30 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 19Buy7.5125,209189,23111,327,380Oct 23 04:19 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 12Buy7.451813411,302,171Oct 15 06:05 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 11Buy7.445339411,302,153Oct 15 06:05 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 09Buy7.2934,896254,21711,302,100Oct 11 04:31 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorOct 01Buy7.562418111,267,204Oct 03 06:16 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 27Buy7.535239211,296,850Oct 01 03:19 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 25Buy7.982,94023,44711,296,798Sep 27 05:08 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 19Buy8.224032911,293,858Sep 21 03:00 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 11Buy8.421714311,465,884Sep 13 04:00 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 06Buy7.844938411,465,867Sep 07 03:21 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorSep 05Buy7.851521,19311,465,818Sep 07 03:21 PM
LEVIN CAPITAL STRATEGIES, L.P.Passive InvestorAug 30Buy7.861814111,465,666Sep 04 06:47 PM